Chr. Hansen is establishing what it describes as a world-class Scientific Advisory Board composed of a set of internationally recognised thought leaders in the field. The company is doing this, it said, to secure continuous and top qualified input and guidance as it explores the exciting opportunities in relation to the human microbiome and “second generation probiotics”.
The Scientific Advisory Board consists of:
· Eric Claassen (Chairman), Professor at Erasmus Medical Centre Rotterdam and at Vrije Universiteit Amsterdam, the Netherlands
· Gary D Wu, Professor of Medicine, Perelman School of Medicine, University of Pennsylvania, USA
· Willem M de Vos, Professor of Microbiology, Wageningen University, the Netherlands, and Helsinki University, Finland
· Robert JM Brummer, Professor of Gastroenterology and Clinical Nutrition, Nutrition-Gut-Brain Interactions Research Centre, Örebro University, Sweden
· Ruth Thieroff-Ekerdt, Founder and Member, Panda Consulting, Mendham, USA
The role of the Scientific Advisory Board is to provide state-of-the-art advice, support and challenge to Chr. Hansen’s management team with respect to developing new probiotic products, guiding the portfolio expansion into the microbiome, clinical trials, and accessing relevant networks and partners across the world.
“The scientific breakthroughs that are occurring with respect to the role of bacteria in human health hold great promise,” said chairman of the Advisory Board Eric Claassen. “As the global leader within probiotics, Chr. Hansen is very well positioned to capitalise on these opportunities, and I look forward to working with the other members of the Advisory Board to help guide Chr. Hansen in capturing these opportunities”
The Scientific Advisory Board will work closely together with the Scientific Committee of Chr. Hansen’s Board of Directors.
